Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
Anna I Guerdjikova,1,2 Nicole Mori,1,2 Leah S Casuto,1,2 Susan L McElroy1,2 1Lindner Center of HOPE, Mason, OH, USA; 2Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA Abstract: Binge eating disorder (BED) is the most common eat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-04-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/novel-pharmacologic-treatment-in-acute-binge-eating-disorder-ndash-rol-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157042842468352 |
|---|---|
| author | Guerdjikova AI Mori N Casuto LS McElroy S |
| author_facet | Guerdjikova AI Mori N Casuto LS McElroy S |
| author_sort | Guerdjikova AI |
| collection | DOAJ |
| description | Anna I Guerdjikova,1,2 Nicole Mori,1,2 Leah S Casuto,1,2 Susan L McElroy1,2 1Lindner Center of HOPE, Mason, OH, USA; 2Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA Abstract: Binge eating disorder (BED) is the most common eating disorder and an important public health problem. It is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control over the binge eating behavior without the inappropriate compensatory weight loss behaviors of bulimia nervosa. BED affects both sexes and all age groups and is associated with medical and psychiatric comorbidities. Until recently, self-help and psychotherapy were the primary treatment options for patients with BED. In early 2015, lisdexamfetamine dimesylate, a prodrug stimulant marketed for attention deficit hyperactive disorder, was the first pharmacologic agent to be approved by the US Food and Drug Administration for the treatment of moderate or severe BED in adults. This article summarizes BED clinical presentation, and discusses the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate in the treatment of BED in adults. Keywords: binging, overeating, Vyvanse, stimulant, approved medication |
| format | Article |
| id | doaj-art-58c70c759f4e412e8976c495beceb402 |
| institution | OA Journals |
| issn | 1178-2021 |
| language | English |
| publishDate | 2016-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj-art-58c70c759f4e412e8976c495beceb4022025-08-20T02:24:17ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212016-04-01Volume 12Issue 183384126477Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamineGuerdjikova AI0Mori NCasuto LSMcElroy S1Lindner Center of HOPEDepartment of Psychiatry and NeuroscienceAnna I Guerdjikova,1,2 Nicole Mori,1,2 Leah S Casuto,1,2 Susan L McElroy1,2 1Lindner Center of HOPE, Mason, OH, USA; 2Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA Abstract: Binge eating disorder (BED) is the most common eating disorder and an important public health problem. It is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control over the binge eating behavior without the inappropriate compensatory weight loss behaviors of bulimia nervosa. BED affects both sexes and all age groups and is associated with medical and psychiatric comorbidities. Until recently, self-help and psychotherapy were the primary treatment options for patients with BED. In early 2015, lisdexamfetamine dimesylate, a prodrug stimulant marketed for attention deficit hyperactive disorder, was the first pharmacologic agent to be approved by the US Food and Drug Administration for the treatment of moderate or severe BED in adults. This article summarizes BED clinical presentation, and discusses the pharmacokinetic profile, efficacy, and safety of lisdexamfetamine dimesylate in the treatment of BED in adults. Keywords: binging, overeating, Vyvanse, stimulant, approved medicationhttps://www.dovepress.com/novel-pharmacologic-treatment-in-acute-binge-eating-disorder-ndash-rol-peer-reviewed-fulltext-article-NDTKey words: binge eatinglisdexamfetamine dimesylatestimulantsovereating |
| spellingShingle | Guerdjikova AI Mori N Casuto LS McElroy S Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine Neuropsychiatric Disease and Treatment Key words: binge eating lisdexamfetamine dimesylate stimulants overeating |
| title | Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_full | Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_fullStr | Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_full_unstemmed | Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_short | Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine |
| title_sort | novel pharmacologic treatment in acute binge eating disorder amp ndash role of lisdexamfetamine |
| topic | Key words: binge eating lisdexamfetamine dimesylate stimulants overeating |
| url | https://www.dovepress.com/novel-pharmacologic-treatment-in-acute-binge-eating-disorder-ndash-rol-peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT guerdjikovaai novelpharmacologictreatmentinacutebingeeatingdisorderampndashroleoflisdexamfetamine AT morin novelpharmacologictreatmentinacutebingeeatingdisorderampndashroleoflisdexamfetamine AT casutols novelpharmacologictreatmentinacutebingeeatingdisorderampndashroleoflisdexamfetamine AT mcelroys novelpharmacologictreatmentinacutebingeeatingdisorderampndashroleoflisdexamfetamine |